Impax Laboratories, Inc.
IPXL
IPXL was delisted on the 4th of May, 2018.
172 hedge funds and large institutions have $1.04B invested in Impax Laboratories, Inc. in 2017 Q2 according to their latest regulatory filings, with 23 funds opening new positions, 61 increasing their positions, 62 reducing their positions, and 29 closing their positions.
32% more capital invested
Capital invested by funds: $792M → $1.04B (+$253M)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
2% less repeat investments, than reductions
Existing positions increased: 61 | Existing positions reduced: 62
3% less funds holding
Funds holding: 178 → 172 (-6)
21% less first-time investments, than exits
New positions opened: 23 | Existing positions closed: 29
21% less call options, than puts
Call options by funds: $1.64M | Put options by funds: $2.06M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MC
Maverick Capital
Dallas,
Texas
|
+$104M |
| 2 |
BM
Bridger Management
New York
|
+$19.8M |
| 3 |
Balyasny Asset Management
Chicago,
Illinois
|
+$12.1M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
+$9.56M |
| 5 |
Stifel Financial
St. Louis,
Missouri
|
+$9.41M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Invesco
Atlanta,
Georgia
|
-$32.6M |
| 2 |
NTC
North Tide Capital
Boston,
Massachusetts
|
-$29.5M |
| 3 |
Millennium Management
New York
|
-$29.1M |
| 4 |
SIG
Senator Investment Group
New York
|
-$13.9M |
| 5 |
PC
PointState Capital
New York
|
-$12.3M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
201
Acadian Asset Management
Boston,
Massachusetts
| – | -$2K | -166 | Closed |
|
|
QCG
202
Quadrant Capital Group
Cincinnati,
Ohio
| – | +$1.03K | +70 | +59% |
|
IPXL Hedge Fund Activity: Q2 2017 in Review
172 of the 4,012 institutional investors tracked by Wall St. Rank reported a position in Impax Laboratories, Inc. (IPXL) for Q2 2017, worth a combined $1.04B — up 32% from $792M a quarter earlier.
Sellers outnumbered buyers: 29 funds closed out of IPXL and 23 opened new positions — a net loss of 6 holders — while 62 trimmed existing stakes and 61 added.
The largest buyer was Maverick Capital, adding an estimated $104M. The largest seller was Invesco, cutting an estimated $32.6M.
- 172 institutional investors held Impax Laboratories, Inc. (IPXL) as of Q2 2017, down from 178 in Q1 2017.
- Funds reported $1.04B of Impax Laboratories, Inc. stock for Q2 2017, up 32% quarter-over-quarter.
- 23 funds opened new Impax Laboratories, Inc. positions in Q2 2017 and 29 closed out, a net change of -6 holders.
- The largest Impax Laboratories, Inc. buyer in Q2 2017 was Maverick Capital, an estimated $104M added.
- The largest Impax Laboratories, Inc. seller in Q2 2017 was Invesco, an estimated $32.6M sold.
Based on aggregated 13F filings for Q2 2017.